Artery Elasticity After Switch From Epzicom to Truvada

Exclusion Criteria

• •Subjects with known resistance to abacavir, lamivudine, tenofovir DF, or emtricitabine at anytime in the past (including but not limited to K65R, L74V/I, M184V/I, or thymidine analog mutations).
• •A new AIDS-defining condition diagnosed (with the exception of CD4 criteria) within 30 days of baseline
• •Previous therapy with agents with systemic myelosuppressive, pancreatoxic, hepatotoxic or cytotoxic potential within 3 months of study entry or the expectation for such therapy at the time of enrollment
• •Proven or suspected acute hepatitis in the 30 days prior to study entry
• •Receiving ongoing therapy with any of the following (administration of any of the following medications must be discontinued at least 30 days prior to the baseline visit and for the duration of the study period):
• •* Nephrotoxic agents (aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, other agents with significant nephrotoxic potential)
• •* Adefovir dipivoxil
• •* Probenecid
• •* Systemic chemotherapeutic agents (i.e., cancer treatment medications)
• •* Systemic corticosteroids
• •* Interleukin-2 (IL-2)
• •Evidence of gastrointestinal malabsorption syndrome or chronic nausea or vomiting which may confer an inability to receive an orally administered medication.
• •Current alcohol or substance abuse judged by the investigator to potentially interfere with subject adherence
• •Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma. Participants with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of baseline and are not anticipated to require systemic therapy during the study.
• •Active, serious infections (other than HIV-1 infection) requiring parenteral antimicrobial therapy within 15 days prior to screening.
• •Prior history of significant renal or bone disease.
• •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
• •Known hypersensitivity to the study drugs, the metabolites or formulation excipients